Cargando…

New Oral Anticoagulants Are Not Superior to Warfarin in Secondary Prevention of Stroke or Transient Ischemic Attacks, but Lower the Risk of Intracranial Bleeding: Insights from a Meta-Analysis and Indirect Treatment Comparisons

PURPOSE: Patients with Atrial Fibrillation (AF) and prior stroke are classified as high risk in all risk stratification schemes. A systematic review and meta-analysis was performed to compare the efficacy and safety of New Oral Anticoagulants (NOACs) to warfarin in patients with AF and previous stro...

Descripción completa

Detalles Bibliográficos
Autores principales: Sardar, Partha, Chatterjee, Saurav, Wu, Wen-Chih, Lichstein, Edgar, Ghosh, Joydeep, Aikat, Shamik, Mukherjee, Debabrata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3808395/
https://www.ncbi.nlm.nih.gov/pubmed/24204920
http://dx.doi.org/10.1371/journal.pone.0077694
_version_ 1782288592972808192
author Sardar, Partha
Chatterjee, Saurav
Wu, Wen-Chih
Lichstein, Edgar
Ghosh, Joydeep
Aikat, Shamik
Mukherjee, Debabrata
author_facet Sardar, Partha
Chatterjee, Saurav
Wu, Wen-Chih
Lichstein, Edgar
Ghosh, Joydeep
Aikat, Shamik
Mukherjee, Debabrata
author_sort Sardar, Partha
collection PubMed
description PURPOSE: Patients with Atrial Fibrillation (AF) and prior stroke are classified as high risk in all risk stratification schemes. A systematic review and meta-analysis was performed to compare the efficacy and safety of New Oral Anticoagulants (NOACs) to warfarin in patients with AF and previous stroke or transient ischemic attack (TIA). METHODS: Three randomized controlled trials (RCTs), including total 14527 patients, comparing NOACs (apixaban, dabigatran and rivaroxaban) with warfarin were included in the analysis. Primary efficacy endpoint was ischemic stroke, and primary safety endpoint was intracranial bleeding. Random-effects models were used to pool efficacy and safety data across RCTs. RevMan and Stata software were used for direct and indirect comparisons, respectively. RESULTS: In patients with AF and previous stroke or TIA, effects of NOACs were not statistically different from that of warfarin, in reduction of stroke (Odds Ratio [OR] 0.86, 95% confidence interval [CI] 0.73- 1.01), disabling and fatal stroke (OR 0.85, 95% CI 0.71-1.04), and all-cause mortality (OR 0.90, 95% CI 0.79 -1.02). Randomization to NOACs was associated with a significantly lower risk of intracranial bleeding (OR 0.42, 95% CI 0.25-0.70). There were no major differences in efficacy between apixaban, dabigatran (110 mg BID and 150 mg BID) and rivaroxaban. Major bleeding was significantly lower with apixaban and dabigatran (110 mg BID) compared with dabigatran (150 mg BID) and rivaroxaban. CONCLUSION: NOACs may not be more effective than warfarin in the secondary prevention of ischemic stroke in patients with a prior history of cerebrovascular ischemia, but have a lower risk of intracranial bleeding.
format Online
Article
Text
id pubmed-3808395
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-38083952013-11-07 New Oral Anticoagulants Are Not Superior to Warfarin in Secondary Prevention of Stroke or Transient Ischemic Attacks, but Lower the Risk of Intracranial Bleeding: Insights from a Meta-Analysis and Indirect Treatment Comparisons Sardar, Partha Chatterjee, Saurav Wu, Wen-Chih Lichstein, Edgar Ghosh, Joydeep Aikat, Shamik Mukherjee, Debabrata PLoS One Research Article PURPOSE: Patients with Atrial Fibrillation (AF) and prior stroke are classified as high risk in all risk stratification schemes. A systematic review and meta-analysis was performed to compare the efficacy and safety of New Oral Anticoagulants (NOACs) to warfarin in patients with AF and previous stroke or transient ischemic attack (TIA). METHODS: Three randomized controlled trials (RCTs), including total 14527 patients, comparing NOACs (apixaban, dabigatran and rivaroxaban) with warfarin were included in the analysis. Primary efficacy endpoint was ischemic stroke, and primary safety endpoint was intracranial bleeding. Random-effects models were used to pool efficacy and safety data across RCTs. RevMan and Stata software were used for direct and indirect comparisons, respectively. RESULTS: In patients with AF and previous stroke or TIA, effects of NOACs were not statistically different from that of warfarin, in reduction of stroke (Odds Ratio [OR] 0.86, 95% confidence interval [CI] 0.73- 1.01), disabling and fatal stroke (OR 0.85, 95% CI 0.71-1.04), and all-cause mortality (OR 0.90, 95% CI 0.79 -1.02). Randomization to NOACs was associated with a significantly lower risk of intracranial bleeding (OR 0.42, 95% CI 0.25-0.70). There were no major differences in efficacy between apixaban, dabigatran (110 mg BID and 150 mg BID) and rivaroxaban. Major bleeding was significantly lower with apixaban and dabigatran (110 mg BID) compared with dabigatran (150 mg BID) and rivaroxaban. CONCLUSION: NOACs may not be more effective than warfarin in the secondary prevention of ischemic stroke in patients with a prior history of cerebrovascular ischemia, but have a lower risk of intracranial bleeding. Public Library of Science 2013-10-25 /pmc/articles/PMC3808395/ /pubmed/24204920 http://dx.doi.org/10.1371/journal.pone.0077694 Text en © 2013 Sardar et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Sardar, Partha
Chatterjee, Saurav
Wu, Wen-Chih
Lichstein, Edgar
Ghosh, Joydeep
Aikat, Shamik
Mukherjee, Debabrata
New Oral Anticoagulants Are Not Superior to Warfarin in Secondary Prevention of Stroke or Transient Ischemic Attacks, but Lower the Risk of Intracranial Bleeding: Insights from a Meta-Analysis and Indirect Treatment Comparisons
title New Oral Anticoagulants Are Not Superior to Warfarin in Secondary Prevention of Stroke or Transient Ischemic Attacks, but Lower the Risk of Intracranial Bleeding: Insights from a Meta-Analysis and Indirect Treatment Comparisons
title_full New Oral Anticoagulants Are Not Superior to Warfarin in Secondary Prevention of Stroke or Transient Ischemic Attacks, but Lower the Risk of Intracranial Bleeding: Insights from a Meta-Analysis and Indirect Treatment Comparisons
title_fullStr New Oral Anticoagulants Are Not Superior to Warfarin in Secondary Prevention of Stroke or Transient Ischemic Attacks, but Lower the Risk of Intracranial Bleeding: Insights from a Meta-Analysis and Indirect Treatment Comparisons
title_full_unstemmed New Oral Anticoagulants Are Not Superior to Warfarin in Secondary Prevention of Stroke or Transient Ischemic Attacks, but Lower the Risk of Intracranial Bleeding: Insights from a Meta-Analysis and Indirect Treatment Comparisons
title_short New Oral Anticoagulants Are Not Superior to Warfarin in Secondary Prevention of Stroke or Transient Ischemic Attacks, but Lower the Risk of Intracranial Bleeding: Insights from a Meta-Analysis and Indirect Treatment Comparisons
title_sort new oral anticoagulants are not superior to warfarin in secondary prevention of stroke or transient ischemic attacks, but lower the risk of intracranial bleeding: insights from a meta-analysis and indirect treatment comparisons
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3808395/
https://www.ncbi.nlm.nih.gov/pubmed/24204920
http://dx.doi.org/10.1371/journal.pone.0077694
work_keys_str_mv AT sardarpartha neworalanticoagulantsarenotsuperiortowarfarininsecondarypreventionofstrokeortransientischemicattacksbutlowertheriskofintracranialbleedinginsightsfromametaanalysisandindirecttreatmentcomparisons
AT chatterjeesaurav neworalanticoagulantsarenotsuperiortowarfarininsecondarypreventionofstrokeortransientischemicattacksbutlowertheriskofintracranialbleedinginsightsfromametaanalysisandindirecttreatmentcomparisons
AT wuwenchih neworalanticoagulantsarenotsuperiortowarfarininsecondarypreventionofstrokeortransientischemicattacksbutlowertheriskofintracranialbleedinginsightsfromametaanalysisandindirecttreatmentcomparisons
AT lichsteinedgar neworalanticoagulantsarenotsuperiortowarfarininsecondarypreventionofstrokeortransientischemicattacksbutlowertheriskofintracranialbleedinginsightsfromametaanalysisandindirecttreatmentcomparisons
AT ghoshjoydeep neworalanticoagulantsarenotsuperiortowarfarininsecondarypreventionofstrokeortransientischemicattacksbutlowertheriskofintracranialbleedinginsightsfromametaanalysisandindirecttreatmentcomparisons
AT aikatshamik neworalanticoagulantsarenotsuperiortowarfarininsecondarypreventionofstrokeortransientischemicattacksbutlowertheriskofintracranialbleedinginsightsfromametaanalysisandindirecttreatmentcomparisons
AT mukherjeedebabrata neworalanticoagulantsarenotsuperiortowarfarininsecondarypreventionofstrokeortransientischemicattacksbutlowertheriskofintracranialbleedinginsightsfromametaanalysisandindirecttreatmentcomparisons